The positive result tees Reata up to file for FDA approval of the activator of Nrf2 and expand development to other neurodegenerative diseases.
Next-gen cancer biotech Checkmate Pharmaceuticals has grabbed a new chief medical officer after a year of C-suite shuffles.
Challenging the old hub model for specialty medications with a tech-enabled platform that improves patient access while reducing time-to-therapy.
Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.
The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.
A clinical trial is a measurement system, but too often, we fail to calibrate the most significant of measurement instruments: trial participants.
University of Pennsylvania scientists designed CAAR-T cells to only target the cells that express autoantibodies in autoimmune diseases.
Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.
As Covance changes up its leadership amid a change at the top of its parent company, one of its former execs has jumped ship to midsize rival CRO.
The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.
Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.
Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.
